Cocrystal Pharma (COCP) Operating Expenses (2010 - 2026)

Cocrystal Pharma (COCP) has 16 years of Operating Expenses data on file, last reported at $2.6 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 10.25% year-over-year to $2.6 million; the trailing twelve-month figure through Mar 2026 stood at $9.3 million (down 42.35% YoY), and the FY2025 full-year result was $9.0 million, down 49.55% from the prior year.
• Operating Expenses improved to $2.6 million in Q1 2026, from $2.5 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $24.4 million in Q2 2022 to a low of $2.1 million in Q3 2025.
• A 5-year average of $5.1 million and a median of $4.3 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses soared 538.14% in 2022 and slumped 82.24% in 2023, its largest moves.
• Tracing COCP's Operating Expenses over 5 years: stood at $4.5 million in 2022, then gained by 3.64% to $4.7 million in 2023, then tumbled by 30.78% to $3.2 million in 2024, then slipped by 23.19% to $2.5 million in 2025, then advanced by 4.03% to $2.6 million in 2026.
• Business Quant data shows COCP's Operating Expenses at $2.6 million in Q1 2026, $2.5 million in Q4 2025, and $2.1 million in Q3 2025.